High Throughput Screening (HTS) Market Revenue to Attain USD 71.11 Bn by 2035
Published: 25 Mar 2026
Author: Precedence Research
High Throughput Screening (HTS) Market Revenue and Trends 2026 to 2035
The global high throughput screening (HTS) market revenue surpassed USD 25.55 billion in 2025 and is predicted to attain around USD 71.11 billion by 2035, growing at a CAGR of 10.78%. This market is growing due to the rising focus of the pharmaceutical, biotechnology, and chemical industries to speed up manufacturing processes.
What Drives the High Throughput Screening (HTS) Market
The market is driven by an increasing focus on drug repurposing, which helps identify new uses for existing drugs, reducing development time and cost. Rising research funding and open innovation models in pharmaceutical and biotechnology companies also support market growth. The growing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases is increasing the need for advanced drug discovery technologies. Additionally, collaborations between pharmaceutical firms, research institutions, and technology providers are accelerating the adoption of automated HTS platforms.
Segment Insights
- By product and services, the consumables segment dominated the market with the maximum share in 2025. This segment’s dominance is driven by the frequent use of consumables like assay kits, reagents, microplates, and detection substrates, with their wide application in drug discovery, toxicology, stem cell research, and biomarker identification further boosting demand in research labs.
- By technology type, the cell-based assay segment led the market with the largest share in 2025, driven by its ability to provide biologically relevant insights into how compounds interact with living cells. The shift from traditional 2D cultures to advanced 3D cell models has further improved their accuracy and predictive value in drug discovery.
- By end use case, the pharmaceutical & biopharmaceutical companies segment dominated the market with the highest market share in 2025. This dominance is driven by intense competition in drug development, pushing companies to identify new therapeutic candidates faster. As a result, these firms are expanding R&D and relying on outsourced research, boosting demand for HTS technologies.
- By application case, the drug discovery programs segment dominated the market with the highest share in 2025. This is because HTS allows researchers to quickly test thousands of compounds, helping speed up the discovery of potential drug candidates. Its integration with advanced automation and data analytics also helps pharmaceutical companies streamline lead identification and optimization more efficiently.
Regional Insights
North America dominated the high throughput screening (HTS) market by holding the maximum share in 2025. This dominance is supported by the strong presence of leading pharmaceutical and biotechnology companies, advanced research infrastructure, and significant investments in drug discovery and life science research. The region also benefits from substantial funding from organizations such as the National Institutes of Health and the high concentration of major pharmaceutical firms in the U.S., which accelerates the adoption of automated screening technologies.
Asia Pacific is expected to grow at the fastest rate in the market during the forecast period. This growth is driven by the rapid expansion of the pharmaceutical and biotechnology industries and rising chronic disease cases. Increasing investments in research and development, along with supportive government initiatives, are strengthening biotechnology hubs in countries such as China, Japan, and India.
High Throughput Screening (HTS) Market Coverage
| Report Attribute | Key Statistics |
| Market Revenue in 2025 | USD 25.55 Billion |
| Market Revenue by 2035 | USD 71.11 Billion |
| CAGR from 2026 to 2035 | 10.78% |
| Quantitative Units | Revenue in USD million/billion, Volume in units |
| Largest Market | North America |
| Base Year | 2025 |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa |
Recent Development
- On March 5, 2026, Carterra launched the Vega high-throughput surface plasmon resonance platform, the first 48-channel SPR system for label-free biomolecular screening. The platform delivers about a 12-fold increase in throughput and can analyze over 20,000 small-molecule interactions daily.(Source: https://www.biospace.com)
Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/8120
You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344